The at-home Gauss COVID-19 rapid antigen test kit helps patients to conduct the test using a smartphone and a lateral flow assay, Credit: Kroger.

Kroger Health has collaborated with Gauss to provide a smartphone-enabled, at-home Covid-19 rapid antigen test kit to patients in the US.

The Gauss COVID-19 Rapid Antigen Test kit is currently awaiting the emergency use authorisation (EUA) from the Food and Drug Administration (FDA).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will provide patients with affordable access to new testing technology, which was developed by Gauss.

Following FDA’s authorisation, the solution is expected to be the first rapid Covid-19 test, which can be completed using a smartphone and a lateral flow assay without using a laboratory, a telemedicine visit, or any specialised electronics.

Additionally, Kroger is planning to make the Covid-19 test kit available for purchase on its website and at its 2,200 pharmacies across the US.

Kroger Health president Colleen Lindholz said: “Since the start of the Covid-19 pandemic, Kroger Heath has remained committed to helping people live healthier lives by offering a variety of Covid-19 testing solutions supported by our multi-disciplinary team of licensed, trained, and experienced healthcare providers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We’re proud to partner with Gauss to expand our COVIDCare+ suite with the forthcoming launch of this affordable, innovative solution.”

Developed by Gauss and biotechnology company Cellex, the test is powered by an encrypted, easy-to-use smartphone application.

Patients who need to use the test should follow video instructions in an application to properly collect the nasal swab and complete the rapid antigen test.

Using patent-pending, artificial intelligence-based technology, the app provides results to the patients in seconds and helps to reduce the reader variability.